echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hengrui Medicine: SHR7280 tablets for the treatment of prostate cancer approved for clinical trials

    Hengrui Medicine: SHR7280 tablets for the treatment of prostate cancer approved for clinical trials

    • Last Update: 2021-08-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On the 25th, Hengrui Pharmaceuticals announced that the company has recently received a "Drug Clinical Trial Approval Notice" for SHR7280 tablets issued by the State Food and Drug Administration, and clinical trials will be launched in the near future


    SHR7280 is an oral small molecule GnRH receptor antagonist, which can block the binding of endogenous GnRH and GnRH receptor, inhibit the synthesis and release of luteinizing hormone and follicle stimulating hormone and other gonadotropins, and reduce testosterone and estradiol And other sex hormone levels


    Up to now, SHR7280 related research and development projects have invested a total of approximately RMB 50.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.